Soleno Therapeutics Announces Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome

Stock Information for Soleno Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.